Johnson & Johnson delays delivery after thrombosis cases!

After the first cases of thrombosis, the European Medicines Agency (EMA) is examining a possible connection between Johnson & Johnson’s corona vaccine and an increased risk of thrombosis. In Europe, Johnson & Johnson is therefore deliberately delaying deliveries of the vaccine.

After the corona vaccine from  AstraZeneca  can only be vaccinated in people over 60 years of age after thrombosis cases in younger people in Germany, the EMA also checks the vaccine from  Johnson  & Johnson after the first cases. The pharmaceutical company is stopping deliveries “proactively” until the EMA has completed its review and is interrupting the supply chains to the European Union that have already been started. In the USA, the authorities are already recommending a vaccination stop and a necessary review of the vaccine after six cases of thrombosis.

Johnson & Johnson: First cases of thrombosis reported

In a press release, the EMA announced that four serious cases of blood clots and  thrombosis  had been reported after the corona vaccination with the Johnson & Johnson vaccine. The number has now increased to six cases. Similar to the side effects of AstraZeneca, three of the six cases were found to have particularly low blood platelet (thrombocyte) counts and thus possible  thrombocytopenia  after vaccination.

One of the cases occurred in a clinical trial, the others in the United States. While approval was granted in Europe on March 11, vaccination in the United States has so far only been granted with an emergency approval. According to previous planning, the vaccine should be available in Germany from April 19th.

EMA examines thrombosis cases around Johnson & Johnson

The EMA perceives the previous cases as a warning signal and devotes itself to a detailed examination of the vaccine. The vaccine and the previous cases should be examined intensively and appropriate measures and recommendations should then be made.

Like AstraZeneca, the Johnson & Johnson vaccine is a vector vaccine. This means that the “blueprint” for part of the  coronavirus , namely the spike protein, is transported via a vector. Harmless viruses that cannot multiply in the body serve as vectors. It is suspected that there may be a connection between thrombosis and vector vaccines. So far, a corresponding investigation into the vaccine from AstraZeneca has taken place.

 

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *